Policy | November 11, 2025
Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Enabling a new era in minimally invasive obesity treatment across Europe
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Relmada expects to initiate its Phase 3 program in the first half of 2026
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Subscribe To Our Newsletter & Stay Updated
